Last updated: October 28, 2026
Apidra (insulin glulisine) is a rapid-acting recombinant insulin marketed by Sanofi. Its commercial position is mature, with competition from insulin lispro, insulin aspart, faster-acting formulations, authorized generics, biosimilar-style follow-on insulins, and lower-cost human insulin. Sanofi does not publicly report Apidra revenue as a separate line item, so the product’s precise financial trajectory cannot be calculated from company filings. The available evidence supports a conclusion of declining strategic importance, continuing cash generation in selected markets, and limited patent-based protection.
What is Apidra and how does it compete in rapid-acting insulin?
Apidra contains insulin glulisine, a recombinant rapid-acting insulin analog. It is approved for improving glycemic control in adults and pediatric patients with diabetes mellitus and is administered by subcutaneous injection or continuous subcutaneous insulin infusion in appropriate patients. Its onset and duration are broadly comparable to other mealtime insulin analogs, although product selection is often driven by formulary access, device compatibility, pricing, and physician familiarity rather than clinically decisive differentiation. (U.S. Food and Drug Administration [FDA], 2024a)
How does Apidra compare with Humalog, NovoLog, Fiasp, and Lyumjev?
| Product |
Active ingredient |
Manufacturer |
Core commercial position |
| Apidra |
Insulin glulisine |
Sanofi |
Mature rapid-acting analog |
| Humalog |
Insulin lispro |
Eli Lilly |
Large installed base and broad device ecosystem |
| Lyumjev |
Insulin lispro-aabc |
Eli Lilly |
Faster-acting lispro formulation |
| NovoLog |
Insulin aspart |
Novo Nordisk |
Large global franchise and pump presence |
| Fiasp |
Faster-acting insulin aspart |
Novo Nordisk |
Faster-acting formulation with premium positioning |
| Afrezza |
Inhaled human insulin |
MannKind |
Non-injectable alternative with limited scale |
Apidra’s main disadvantages are commercial rather than pharmacological. It lacks the growth profile of newer delivery systems, has limited public evidence of a differentiated premium price, and competes in a category where payers have substantial negotiating leverage. The product also faces switching pressure from biosimilar and follow-on insulin programs.
When did Apidra receive FDA approval and what is its regulatory status?
The FDA approved Apidra in 2004 under New Drug Application 021629. The initial approval covered subcutaneous use in adults with type 1 or type 2 diabetes. The label was later expanded and updated for pediatric use and insulin-pump administration. (FDA, 2004; FDA, 2024a)
Is Apidra regulated as a biologic or a conventional drug?
Apidra was originally approved under the drug pathway used for insulin products before the statutory transition of insulin products to the Public Health Service Act framework. The FDA’s insulin transition converted approved insulin products from NDAs to biologics licenses on March 23, 2020. That transition created a clearer pathway for follow-on insulin products and biosimilar applications. (FDA, 2020)
Apidra therefore occupies an unusual regulatory position:
- It originated as an NDA-approved insulin product.
- It is now subject to the biologics framework for purposes of follow-on competition.
- It can face competition from products approved through abbreviated or biosimilar-style pathways.
- Its regulatory history does not provide the market exclusivity associated with newer biologics.
What is the Orange Book status of Apidra?
Apidra’s historical approval was recorded in the Orange Book because it originated as an NDA product. After the insulin transition, biologic reference-product information is more appropriately assessed through FDA biologics databases and the Purple Book framework, together with the product’s original NDA history.
The commercial implication is that Apidra’s practical protection is no longer determined primarily by Orange Book patent listings. Follow-on insulin competition can arise through regulatory pathways that do not depend exclusively on a traditional Paragraph IV generic challenge.
Does Apidra have active market exclusivity?
Apidra’s statutory and regulatory exclusivity periods have expired. It was approved in 2004, and any standard new-drug exclusivity associated with that approval ended many years ago. No current regulatory exclusivity is publicly associated with Apidra that would prevent follow-on insulin competition.
What patents protect Apidra and when do they expire?
Apidra’s principal composition and formulation protection was tied to insulin-glulisine technology developed before launch. Public patent records identify historical Sanofi-related insulin patents, but the commercially relevant exclusivity period has expired or has been substantially eroded.
| Protection category |
Commercial relevance |
| Insulin-glulisine composition and derivative patents |
Historical protection; no longer a meaningful barrier to entry |
| Formulation patents |
May address stabilizers, concentration, or pharmaceutical composition; generally limited against alternative formulations |
| Delivery-device rights |
Can protect pens, cartridges, or pump interfaces, but usually do not block insulin-glulisine competition |
| Method-of-use patents |
Limited value where claims cover routine mealtime insulin treatment |
| Manufacturing know-how |
Potentially important operational barrier, but not a statutory market exclusivity right |
Patent status must be evaluated claim by claim, jurisdiction by jurisdiction, and against current patent-family members. The original Apidra patent estate does not provide a durable U.S. franchise comparable to a recently launched biologic with unexpired composition patents.
Are there Paragraph IV challenges or biosimilar threats to Apidra?
No major, publicly visible Paragraph IV litigation campaign has defined Apidra’s U.S. market in the manner seen with small-molecule blockbusters. The more relevant competitive risk is follow-on insulin competition under the post-2020 biologics framework.
What is the biosimilar risk for insulin glulisine?
The risk is moderate to high over the long term, but the timing depends on development economics and market access. Insulin is a complex biologic, yet the molecule has a long clinical history and established analytical standards. A competing manufacturer may rely on:
- A biosimilar application under section 351(k).
- A follow-on insulin strategy based on the product’s regulatory classification.
- An alternative insulin product with comparable clinical use.
- A private-label or authorized-generic arrangement.
- A device-centered substitution strategy using the same or comparable active ingredient.
The main barrier is not proof of clinical novelty. It is manufacturing scale, batch consistency, device integration, payer access, and the ability to compete in a rebate-heavy market.
What formulations and delivery systems are protected?
Apidra is available in vial and prefilled-pen presentations in certain markets, with availability varying by country and product configuration. The formulation contains insulin glulisine with excipients used to stabilize and deliver the product. The commercial protection of these formulations is weak relative to composition patents because competitors can pursue different excipient combinations, containers, concentrations, or delivery devices.
Does Apidra have meaningful device protection?
Device rights can protect a specific pen or cartridge configuration, but they generally do not prevent a competing manufacturer from selling insulin glulisine or another rapid-acting insulin in a different device. The most relevant device risk is substitution at the pharmacy or formulary level, where the payer may prefer a competing pen, vial, or pump-compatible product.
How has Apidra’s market position changed?
Apidra entered a market with strong demand for rapid-acting insulin analogs. Its later trajectory has been shaped by four forces:
- Mature diabetes prevalence and durable insulin demand.
- Heavy price competition among insulin analogs.
- Payer pressure and rebate-based contracting.
- Product switching toward faster-acting formulations, connected pens, and pump ecosystems.
The market remains large, but volume growth does not translate directly into Apidra growth. A mature product can lose share even while the underlying diabetes market expands.
What are the major commercial pressures?
Pricing reform
The U.S. insulin market has undergone direct and indirect price intervention. The Inflation Reduction Act limits insulin cost sharing for many Medicare Part D and Part B beneficiaries to $35 per month, reducing patient exposure but increasing pressure on manufacturers and plans to manage net prices. (Centers for Medicare & Medicaid Services [CMS], 2023)
Sanofi has also implemented lower-price insulin programs and patient-access measures. These programs can expand access while compressing gross-to-net economics.
Formulary competition
Apidra competes against entrenched formulary preferences for Humalog and NovoLog. Payers often award preferred status to one or two rapid-acting analogs in exchange for rebates. That structure can produce abrupt volume shifts independent of clinical performance.
Channel concentration
A substantial share of insulin economics is determined by wholesalers, pharmacy benefit managers, retail pharmacies, hospitals, and government programs. Manufacturer list price therefore provides an incomplete view of realized revenue.
What is Apidra’s financial trajectory?
Sanofi does not disclose Apidra revenue as a standalone product in its annual reporting. The company reports diabetes products within broader business categories, and public filings do not isolate Apidra sales, gross margin, operating profit, or geographic revenue. (Sanofi, 2024)
The defensible financial assessment is therefore directional:
| Period |
Financial interpretation |
| 2004 to early commercial maturity |
Revenue expansion as rapid-acting analog adoption increased |
| Mature franchise period |
Stable demand but intense competition and rebate pressure |
| Post-insulin-price-reform period |
Lower net pricing and greater access-related pressure |
| Current phase |
Harvest-oriented product with limited patent upside and higher substitution risk |
Apidra may continue to generate revenue because insulin demand is recurring and treatment switching can be gradual. Its financial value is constrained by limited pricing power, weak exclusivity, and the cost of maintaining global manufacturing, regulatory, pharmacovigilance, and distribution infrastructure.
What is Sanofi’s revenue exposure to Apidra?
The exact exposure is not publicly quantifiable. Sanofi’s diabetes portfolio has historically included Toujeo, Lantus, Soliqua, and Apidra. Lantus and Toujeo have been more commercially significant within the company’s insulin portfolio, while Apidra is a smaller rapid-acting component. The absence of separate reporting indicates that Apidra is not material enough to require standalone disclosure under Sanofi’s reporting structure.
Which companies are challenging Apidra commercially?
Apidra faces competition from established multinational manufacturers rather than a single dominant challenger.
| Company |
Competing product or strategy |
Risk to Apidra |
| Eli Lilly |
Humalog and Lyumjev |
Formulary displacement and faster-acting positioning |
| Novo Nordisk |
NovoLog and Fiasp |
Broad insulin franchise and pump ecosystem |
| Biocon Biologics |
Follow-on and biosimilar insulin capabilities |
Potential lower-cost supply |
| Viatris and partners |
Biosimilar insulin commercialization capabilities |
Price-based competition |
| Wockhardt and regional manufacturers |
Insulin and follow-on development |
Geographic and tender pressure |
| Local manufacturers |
Human insulin and analog alternatives |
Lower-cost substitution in emerging markets |
The most credible near-term threat is not a single Apidra biosimilar launch. It is cumulative erosion from formulary exclusion, regional tender losses, lower-priced alternatives, and switching to competing rapid-acting products.
What patent litigation and settlement agreements affect Apidra?
No major current U.S. patent litigation or settlement agreement appears to control Apidra’s market access. The product’s principal patent-based barriers are aged, and the central commercial issues are pricing, manufacturing, regulatory approval, and payer contracting.
A future dispute could involve:
- Biosimilar interchangeability or substitution.
- Manufacturing-process patents.
- Pen or cartridge design.
- Formulation stability.
- Regulatory exclusivity and reference-product status.
- Trade secrets related to recombinant insulin production.
Any such dispute would be more likely to affect launch timing, manufacturing economics, or device substitution than to restore broad molecule-level exclusivity.
How strong is the Apidra patent estate?
The Apidra patent estate is weak as a current market barrier.
| Factor |
Assessment |
| Composition protection |
Aged and commercially limited |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Narrow and design-around risk is high |
| Device protection |
Relevant only to specific presentations |
| Method-of-use protection |
Limited for established insulin treatment |
| Manufacturing know-how |
Potentially meaningful but difficult to enforce against independent production |
| Litigation leverage |
Low relative to newly launched biologics |
The product retains technical complexity, but technical complexity is not the same as enforceable patent strength.
What generic or biosimilar launch scenarios exist?
Three scenarios are commercially plausible.
Scenario 1: Gradual erosion without a direct biosimilar
Apidra remains available but loses formulary share to Humalog, NovoLog, Fiasp, Lyumjev, and lower-cost insulin products. This is the lowest-disruption scenario.
Scenario 2: Regional follow-on competition
A competing insulin glulisine or comparable rapid-acting insulin launches first in price-sensitive markets, hospital tenders, or countries with less concentrated reimbursement. Sanofi experiences volume losses outside the United States before a major U.S. event.
Scenario 3: U.S. follow-on or biosimilar entry
A U.S. competitor secures FDA approval and obtains preferred formulary placement through aggressive net pricing. Apidra could experience rapid erosion because insulin products are readily substitutable within many payer protocols.
How does Apidra compare with competing insulin patent estates?
Apidra has less defensible lifecycle protection than newer rapid-acting products with specialized formulations or delivery technologies. Fiasp and Lyumjev may have stronger formulation and method-of-use positions around faster pharmacokinetics, but their protection is still vulnerable to product-specific design-around strategies. Humalog and NovoLog have older estates but benefit from entrenched formularies, device adoption, manufacturing scale, and physician familiarity.
Apidra’s competitive weakness is therefore not only patent expiry. It is the combination of limited differentiation and a market where commercial scale matters more than molecule ownership.
Key Takeaways
- Apidra is Sanofi’s rapid-acting insulin glulisine product, first approved by the FDA in 2004.
- Its regulatory exclusivity has expired, and its historical patent estate does not provide a meaningful current U.S. barrier.
- Apidra is exposed to Humalog, Lyumjev, NovoLog, Fiasp, follow-on insulins, and lower-cost human insulin.
- No major current Paragraph IV litigation defines the product’s market.
- The principal competitive risk is biosimilar or follow-on insulin substitution, supported by payer pressure and the post-2020 insulin regulatory framework.
- Sanofi does not separately report Apidra revenue, preventing a precise product-level sales or profit estimate.
- The financial trajectory is consistent with a mature, declining or low-growth franchise under net-price pressure.
- Manufacturing capability, device integration, formulary access, and supply reliability are more important than remaining molecule-level patent rights.
FAQs About Apidra Market and Patent Risk
Is Apidra still sold in the United States?
Apidra remains an FDA-approved product, but availability can differ by presentation, distributor, pharmacy, and market. FDA approval does not guarantee uninterrupted commercial supply of every vial or pen configuration. (FDA, 2024a)
Can a biosimilar replace Apidra automatically at the pharmacy?
Automatic substitution depends on FDA interchangeability status, state law, payer policy, and the product’s dispensing channel. A follow-on insulin may compete commercially without receiving automatic substitution treatment.
Is insulin glulisine the same as insulin lispro?
No. Insulin glulisine and insulin lispro are different rapid-acting insulin analogs. They have similar therapeutic roles but distinct molecular sequences, regulatory histories, and patent families.
Does Apidra work with insulin pumps?
The Apidra label permits use in continuous subcutaneous insulin infusion systems under specified conditions. Pump compatibility can vary by device labeling and market. (FDA, 2024a)
Is Apidra a growth product for Sanofi?
Public filings do not identify Apidra as a standalone growth driver. Its commercial profile is more consistent with a mature portfolio product exposed to competition, price controls, and formulary management. (Sanofi, 2024)
References
Centers for Medicare & Medicaid Services. (2023). Medicare insulin cost-sharing provisions under the Inflation Reduction Act. https://www.cms.gov
Sanofi. (2024). 2023 universal registration document and annual financial report. https://www.sanofi.com
U.S. Food and Drug Administration. (2004). FDA approves Apidra (insulin glulisine) for diabetes treatment. https://www.fda.gov
U.S. Food and Drug Administration. (2020). Transition of insulin products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act. https://www.fda.gov
U.S. Food and Drug Administration. (2024a). Apidra prescribing information. https://www.accessdata.fda.gov
